CHARTWELL NEWS
  • MIKE LITZINGER JOINS AMERICAN BANK AS HEAD OF INTERNAL AUDIT

    Chartwell Partners congratulates our placement Mike Litzinger on his new role as Director of Internal Audit at American Bank in Austin.  As Director of Internal Audit, Litzinger will be responsible for leading and developing the Internal Audit function. He brings a strong background in Internal Audit from the public accounting sector and will be a…

  • Jaguar Gene Therapy Bolsters Leadership Team with Appointment of Joseph W. McIntosh, MD, as Chief Medical Officer

    Chartwell Partners is pleased to announce the recruitment of Joe McIntosh, MD, as Chief Medical Officer for Jaguar Gene Therapy. Backed by Deerfield Management, ARCH Venture Partners, Goldman Sachs, Nolan Capital, and Eli Lilly, and based in Lake Forest, IL, Jaguar Gene Therapy is led by former AveXis leadership, leveraging a proven management team with the…

  • Chartwell Partners Recruits Ian Hunt to Akebia Therapeutics as SVP, Regulatory Affairs

    We are delighted to announce the recruitment of Ian Hunt as SVP, Regulatory Affairs for Akebia Therapeutics, a public, Cambridge, MA-based biopharmaceutical company committed to bettering the lives of people impacted by kidney disease. Most recently, Ian served as Vice President and Head of Regulatory Affairs for GSK’s Infectious Disease, Neuroscience and CV/Renal franchises, a…

  • INDEPENDENT FINANCIAL NAMES MARY BAILEY CHIEF COMPLIANCE OFFICER

    Chartwell Partners is pleased to announce the placement of Mary Bailey as Chief Compliance Officer at Independent Financial.  Bailey will be responsible for aligning the compliance function and strategy of the institution to its ambitious growth goals while developing, executing and monitoring the compliance strategy enterprise wide. Most recently, Bailey served in compliance consulting roles…

  • BioCryst Pharmaceuticals Appoints Salisa Hauptmann, MPH as SVP, Regulatory Affairs

    Chartwell Partners is pleased to announce the appointment of Salisa Hauptmann, MPH, as Senior Vice President, Regulatory Affairs for BioCryst Pharmaceuticals, a company pioneering the discovery, development and commercialization of oral, small molecule medicines to treat rare diseases. Salisa brings more than 25 years of global regulatory expertise to BioCryst, including significant work with rare,…

  • Rare Disease Biotech Company, EryDel, names Esin Kosal, PhD as SVP, Regulatory Affairs

    Chartwell Partners is pleased to announce the recruitment of Esin Kosal, PhD as SVP, Regulatory Affairs for EryDel SpA, a global biotechnology company utilizing its proprietary red blood cell drug delivery technology to encapsulate small and large molecules into a patient’s own red blood cells which are then reinfused into that patient in a fast,…